Shattuck Labs News and Activities
Presence
Shattuck Labs develops biotechnology medicines for cancer and immune diseases. Its main services and products include drug discovery, clinical-stage therapies, and protein engineering platforms for healthcare providers, research partners, and patients.
Shattuck Labs products and services overview:
- Cancer therapies
- Immune therapies
- Drug discovery
- Protein engineering
- Clinical development
Revenue: ~$1 million
Employees: 60
Headquarters: Austin, United States (USA)
Shattuck Labs is one of the...
Shattuck Labs is a company listed under the stock ticker STTK (US).
Acquisition, funding and merger involving Shattuck Labs.
- Shattuck Labs has just announced a $103 Million fundraising (posted on August 28 2025).
- Shattuck Labs has just announced a $103 Million fundraising (posted on August 8 2025).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at Shattuck Labs
- Taylor Schreiber, Chief Executive Officer and Director
- Helen Boudreau, Director
- George Golumbeski, Chairman of the Board
Create your alert
to follow the executive moves at Shattuck Labs.
Biotechnology
Shattuck Labs has 2,430 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Tempus has announced the acquisition of Personalis (posted on July 20 2026).
- Eli Lilly has announced the acquisition of AtaiBeckley (posted on July 17 2026).
- GSK has acquired Nuvalent (posted on July 17 2026).
Popular contacts in Biotechnology
News
Press releases by Shattuck Labs
- Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
- Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
- Shattuck Labs Announces Participation in Upcoming March Investor Conferences
- Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
- Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Shattuck Labs to Participate in Upcoming December Investor Conferences
- Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
- Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
- Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
- View more press releases Close
Social media about Shattuck Labs
- Shattuck Labs on Wikipedia, Google News & Yahoo Finance
- Shattuck Labs on LinkedIn, X (Twitter) & YouTube
